UNSPSC 51383402: Etodolac

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C17H21NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2M36281008, chemically known as 1,3,4,9-tetrahydro-1,8-diethylpyrano(3,4-b)indole-1-acetic acid but generally known as etodolac, which bears US NIH Compound Identifier 3308. European Medicines Agency schedules Etodolac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07316MIG.

UNSPSC 51383402 Etodolac is a Commodity code that nominally names a specific nonsteroidal anti-inflammatory drug, but recent state and local procurement activity under this code shows little alignment with that product. The three most recent opportunities posted under this code — a Seminole County, Florida IFB for naloxone and drug deactivation systems; a Texas HHS Commission RFI on direct-to-manufacturer prescription programs; and a Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products — span pharmaceutical procurement broadly rather than etodolac specifically. The mismatch suggests this code is either an administrative catch-all for pharmaceutical categories or is being applied inconsistently by issuing bodies. State and local health departments, cooperative purchasing alliances, and county health agencies are the primary issuing bodies soliciting under this code, with activity driven by demand for inventory management and cost containment across pharmacy benefit programs.

Geographic activity centers on Florida, Texas, and Minnesota, with the MMCAP cooperative (administered by Minnesota's Department of Administration) serving multiple states including Oregon. Representative opportunities include Seminole County's July 2026 IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term; Texas HHS Commission's April 2026 RFI seeking vendor capabilities for direct-to-manufacturer prescription relationships to improve fulfillment efficiency outside traditional pharmacy benefit manager and wholesaler channels; and MMCAP's March 2026 RFP establishing multiple contracts for generic pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), effective July 1, 2026, with evaluations weighted 75 percent on price competitiveness. The code shows limited recent procurement volume under its nominal scope and inconsistent mapping to actual state and local purchasing activity.